Moxonidine-cs Tab n / a film about 0.4mg 14 pc


Moxonidine-cs Tab n / a film about 0.4mg 14 pc



Active substance:
0.4 mg moxonidine
croscarmellose sodium (primelloza) -; 3.0 mg; lactose monohydrate (laktopress) (milk sugar) -; 95.1 mg; colloidal silicon dioxide (Aerosil) -; 0.5 mg; Sodium stearyl fumarate -; 1.0 mg;
Coating: Opadry II (polyvinyl alcohol, partially hydrolyzed – 1.32
mg; titanium dioxide E 171 -; 0.5751 mg; talc -; 0.6 mg; macrogol (polyethylene glycol 3350) -; 0.3705 mg; Soy lecithin E 322 -; 0,105 mg; aluminum lake based on indigo -; 0.0018 mg; Aluminum lacquer dye-based azorubin -; 0.0153 mg; Aluminum lacquer dye crimson [Ponceau 4R] -; 0.0123 mg).
Tablets, film-coated dark pink, round, biconvex. Tablets on a break white or nearly white.
Product form:
Packing 14 pcs.
– increased sensitivity to the active ingredient and the other components of the formulation;
– sick sinus syndrome;
– bradycardia (heart rate less than 50 rest beats / min.);
– atrioventricular block II and III degree;
– The expressed disturbances of heart rhythm;
– acute and chronic heart failure (III-IV NYHA functional class classifying);
– simultaneous use of tricyclic antidepressants (see “Interaction with other drugs.”);
– severe renal impairment (creatinine clearance less than 30 mL / min);
– hemodialysis;
– lactation;
– hereditary lactose intolerance, lactase deficiency or malabsorption glyukozy- galactose;
– age over 75 years;
– the age of 18 years (due to lack of data on safety and efficacy).
Special care is needed when applying Moxonidine in patients with AV block I degree (risk of bradycardia); severe coronary artery disease, severe coronary heart disease, or unstable angina (application experience insufficient), chronic heart failure, severe hepatic impairment, with impaired renal function (creatinine clearance of more than 30 ml / min).
0.4 mg
Arterial hypertension.
Interaction with other drugs
The combined use of Moxonidine with other antihypertensives leads to additive effect. Tricyclic antidepressants may reduce the effectiveness of centrally acting antihypertensive agents, and therefore is not suitable for taking them together with moxonidine.
Moxonidine may exacerbate the effects of tricyclic antidepressants, tranquilizers, ethanol, sedatives and hypnotics.
Moxonidine is able to moderately improve cognitive impairment in patients receiving lorazepam.
Moxonidine may enhance the sedative effect of benzodiazepines in their simultaneous assignment.
Moxonidine is allocated by tubular secretion. It is therefore possible interaction with other drugs, was isolated by tubular secretion. Beta-blockers increase the bradycardia, the severity of the negative foreign-and dromotropic action.
There are reports of a few cases of overdose with no death, when simultaneously used doses up to 19.6 mg.
headache, sedation, marked reduction of blood pressure, dizziness, fatigue, bradycardia, dryness of the oral mucosa, vomiting, fatigue, epigastric pain, respiratory depression and impaired consciousness. Furthermore, there may be also a transient increase in AD, tachycardia and hyperglycemia have been shown in several studies on high doses in animals.
There is no specific antidote. In case of significant decrease in blood pressure may be required to restore blood volume by introducing liquid and dopamine (by injection).
Bradycardia can be stopped by atropine (injecting).
In severe cases of overdose it is recommended to carefully monitor the human consciousness and to prevent respiratory depression.
Alpha-adrenergic antagonists may reduce or eliminate paradoxical hypertensive effects in overdose moxonidine.
Moxonidine slightly displayed during hemodialysis.
pharmachologic effect
Pharmacological group:
Centrally acting antihypertensives
Moxonidine is a antihypertensive agent with a central mechanism of action. Vstvolovyh brain structures (layer rostral lateral ventricles) moxonidine selectively stimulates imidazolin-chuvstvitelnye receptors involved in tonic reflex and regulation of the sympathetic nervous system. Stimulation imi- dazolinovyx receptors reduces peripheral sympathetic activity and blood pressure (BP).
Moxonidine differs from other sympatholytic antihypertensives lower affinity to the alpha2-adrenergic receptors, which explains the lower probability of sedation and dry mouth.
Receiving moxonidine leads to a reduction in systemic vascular resistance and BP. Moxonidine improves by 21% insulin sensitivity index (compared to placebo) in patients with obesity, insulin resistance, and moderate hypertension.
Absorption: After oral administration moxonidine is rapidly and almost completely absorbed in the upper gastrointestinal tract. Absolute bioavailable-ness is approximately 88%. Time to maximum concentration -; about 1 hr. Meal did not affect the pharmacokinetics of the drug.
Communication plasma protein is 7.2%.
The main metabolite -; dehydrogenated moxonidine. The pharmacodynamic activity of dehydrogenated moxonidine -; about 10% compared with moxonidine.
The half-life (T1 / 2) of moxonidine and metabolite of 2.5 and 5 hours, respectively. Within 24 hours over 90% moxonidine excreted by the kidneys (approximately 78% unchanged and 13% as a dehydro-romoksonidina, other metabolites in urine do not exceed 8% of the dose). Less than 1% of the dose is excreted through the intestines.
Pharmacokinetics in patients with arterial hypertension th:
Compared to healthy volunteers in hypertensive patients did not report changes in the pharmacokinetics of moxonidine.
Pharmacokinetics in elderly
It is noted clinically insignificant change in pharmacokinetic parameters moxonidine in elderly patients, probably due to decrease in the intensity of its metabolism and / or somewhat higher biodostypnostyu.
Pharmacokinetics in children
Moxonidine is not recommended for use in patients younger than 18 years, and therefore in this group pharmacokinetic studies have not been conducted.
Pharmacokinetics in renal failure
Excretion Moxonidine largely correlates with creatinine clearance (CC). In patients with moderate renal impairment (creatinine clearance in the range of 30-60 ml / min) Equilibrium concentration in plasma and the end of T1 / 2 of about 2, and l, 5-fold higher than in patients with normal renal function (creatinine clearance greater than 90 mL / min.).
In patients with severe renal failure (creatinine clearance less than 30 mL / min.), The equilibrium concentration in the blood plasma and the final T1 / 2 to 3 times higher than in patients with normal renal function. Assigning multiple doses of moxonidine leads to a predictable accumulation in the body of patients with moderate and severe renal insufficiency. Patients with end-stage renal failure (creatinine clearance less than 10 mL / min) nahodya- schihsya dialysis, equilibrium concentrations in the blood and the end of T1 / 2, respectively, in the plasma 4 and 6 times higher than in patients with normal renal function. In all groups, the maximum concentration of moxonidine in the plasma above 1.5 – 2 times. In patients with impaired renal function, dosage should be individualized. Moxonidine slightly displayed during hemodialysis.
Pregnancy and breast-feeding
Clinical data on the use of moxonidine in pregnant women are not available.
In animal studies embryotoxic effect of the drug was found. Moxonidine should be administered to pregnant women only after careful evaluation of the risk-benefit ratio when the benefit to the mother outweighs the potential risk to the fetus.
Moxonidine passes into breast milk and therefore should not be administered during breast-feeding. If necessary, use of moxonidine during lactation, breast-feeding should be discontinued.
Conditions of supply of pharmacies
On prescription
side effects
The frequency of side effects listed below, was determined according to the following: very often (> 1/10); common (> 1/100,
special instructions
If necessary, cancel the concomitant beta-blockers and drug Moxonidine, first override beta-blockers, and only a few days Moxonidine.
There is currently no evidence that discontinuation of the drug Moxonidine leads to increased blood pressure. However, do not stop taking the drug Moxonidine sharply, instead, gradually reduce the dose of the drug for two weeks.
During treatment to eliminate the use of alcohol.
During treatment requires regular monitoring of heart rate and ECG.
Effect of moxonidine on the ability to drive vehicles or operate machinery has not been studied. However, taking into account the possibility of dizziness, drowsiness, patients should be careful during the occupation of potentially hazardous activities that require attention, such as driving a vehicle or operating machinery which requires high concentration of attention.
Storage conditions
In a dry place, protected from light at a temperature not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
Inside, regardless of the meal. In most cases, the initial dose of the drug Moxonidine is 0.2 mg per day. The maximum single dose is 0.4 mg. The maximum daily dose to be divided into 2 doses is 0.6 mg. Requires an individual correction of the daily dose, depending on patient tolerability of the therapy. No dose adjustment for patients with hepatic impairment is not required. The starting dose for patients with moderate or severe renal impairment is 0.2 mg / day. If necessary and if tolerated daily dose may be increased to a maximum of 0.4 mg.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review